Maria Mercado, MD
Endocrinology, Diabetes & Metabolism · Chula Vista, CANPI 1851335723
Payments from drug & device makers
Across 263 payments — averaging $28.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Lilly USA, LLC$682
- Medtronic$581
- AstraZeneca$517
- Amgen$500
- Tandem Diabetes Care, Inc.$499
- plus $2K from 23 others
What the payments were for
- Food & beverage$7,08995%
- Education$2283%
- Gifts$1192%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 127 | $2,189 |
| Lilly USA, LLC | 36 | $682 |
| Medtronic | 10 | $581 |
| AstraZeneca | 13 | $517 |
| Amgen(2 entities) | 6 | $500 |
| Tandem Diabetes Care, Inc. | 17 | $499 |
| Sanofi-aventis U.S. LLC | 4 | $308 |
| Mannkind Corporation | 9 | $283 |
| Ascendis Pharma Endocrinology Inc | 4 | $268 |
| Abbott | 3 | $232 |
| Xeris Pharmaceuticals, Inc. | 4 | $189 |
| Dexcom, Inc. | 7 | $185 |
| BETA Bionics, Inc. | 3 | $170 |
| Boehringer Ingelheim | 2 | $146 |
| IBSA Pharma Inc. | 1 | $122 |
| Corcept Therapeutics | 1 | $122 |
| Acella Pharmaceuticals, LLC | 2 | $89 |
| Exelixis Inc. | 1 | $87 |
| AbbVie | 2 | $48 |
| Radius Health, Inc. | 2 | $46 |
| Bigfoot Biomedical Inc | 1 | $26 |
| Lexicon Pharmaceuticals, Inc. | 1 | $25 |
| Zealand Pharma US, Inc. | 1 | $21 |
| Pfizer | 1 | $21 |
| Companion Medical, Inc. | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $20 |
| Cequr Corporation | 1 | $14 |
| Insulet Corporation | 1 | $13 |
| Lifescan, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$740
- MINIMED 780G$422
- TEPEZZA$413
- iLet Bionic Pancreas$375
- FARXIGA$370
- RYBELSUS$250
- FreeStyle Lite system$200
- t:slim X2 Insulin Pump with Control-IQ$143
- Tresiba$125
- RECORLEV$124
- TZIELD$124
- Tirosint$122
- Korlym$122
- Yorvipath$121
- JARDIANCE$120
How this compares
$7,435 in reported general payments places this provider in the 70th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 262 | $362,791 |
| JardianceEmpagliflozin | 144 | $186,014 |
| TrulicityDulaglutide | 97 | $138,375 |
| MounjaroTirzepatide | 77 | $95,772 |
| RybelsusSemaglutide | 46 | $76,893 |
| Tresiba Flextouch U-200Insulin Degludec | 44 | $50,054 |
| FarxigaDapagliflozin Propanediol | 19 | $28,312 |
| Humalog Kwikpen U-100Insulin Lispro | 80 | $23,114 |
| Tresiba Flextouch U-100Insulin Degludec | 35 | $21,384 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 12 | $20,948 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 18 | $20,902 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 135 | $19,660 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $17,961 |
| Novolog FlexpenInsulin Aspart | 44 | $16,367 |
| SynthroidLevothyroxine Sodium | 134 | $12,359 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6 | $2,189 | $460,632320 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro | $682 | $243,024205 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy | $146 | $216,010177 claims |
| AstraZenecaFarxiga | $517 | $28,31219 claims |
| AbbVieSynthroid | $48 | $12,359134 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $308 | $11,12113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Chula Vista
- Jerrold OlefskySan Diego$26.5M
- Mark ChristiansenWalnut Creek$22.9M
- Timothy BaileyEscondido$22.3M
- Stanley HsiaLos Angeles$19.8M
- Juan FriasSan Diego$14.1M
- Paul NorwoodFresno$6.2M
- Athena Philis-Tsimikasla Jolla$6M
- David AhnNewport Beach$5.8M
- Shlomo MelmedLos Angeles$3.3M
- Leila ChaychiSan Carlos$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.